Skip to main content
Full access
Departments
Published Online: 1 April 2014

Worsening of Psychosis With Aripiprazole

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Aripiprazole, a dopamine–serotonin system stabilizer is a partial agonist at D2 and 5HT−1A receptors and a partial antagonist at 5HT2A receptors. It increases dopamine levels in a hypodopaminergic state and decreases dopamine levels in a hyperdopaminergic state.1 We describe a patient with acute worsening of psychotic symptoms after initiation of aripiprazole.

Case Report

A 33-year-old woman was admitted because of significant disorganized behavior. There was a history of heavy alcohol use in the preceding few weeks with cognitive and vegetative depressive symptoms. On examination she was disheveled and poorly groomed, perplexed, and fearful. She expressed mood congruent delusions of guilt and persecution associated with second person command auditory hallucinations.
An initial diagnosis of alcohol withdrawal with associated psychotic symptoms, with a differential diagnosis of depressive episode with melancholic symptoms was made. She did not have any withdrawal symptoms on AWS after 48 hours. She was started on mirtazapine 15 mg for the depressive symptoms, increasing the dose to 30 mg after a few days. There was significant improvement in her mood, and the acute perceptual disturbances settled without the addition of antipsychotic medications. The collateral information from the family revealed low grade suspiciousness and mistrust of family members for a few years. There was a strong family history of schizophrenia in her brother and bipolar affective disorder in her maternal grandmother.
She continued to have persecutory and referential ideas to which she had insight and she did not act on these beliefs. Because of the family history of schizophrenia and ongoing referential themes in her thought, it was decided to start her on an antipsychotic medication. Aripiprazole was chosen because of its favorable side effect profile in regard to weight gain. She was commenced on 10 mg daily for 5 days after which the dose was increased to 15 mg per day.
There was a gradual deterioration of her mental status over the week following the introduction of aripiprazole with re-emergence of persecutory and referential delusions and auditory hallucinations. The dose of aripiprazole was increased considering the worsening of symptoms. There was no ongoing drug use in the ward. There was a dramatic deterioration over the next several days with the patient responding to auditory hallucinations and intense persecutory delusions. Aripiprazole was stopped, and she was started on olanzapine (10 mg two times per day). She rapidly improved and over the following 10 days there was complete resolution of her psychotic symptoms.
There are case reports of aripiprazole worsening psychosis in patients.24 There have been reports of worsening of psychosis when aripiprazole was added to patients who were being prescribed haloperidol. A background hypodopaminergic state induced by haloperidol may have potentiated the dopamine agonist activity of aripiprazole.4 Interestingly, alcohol withdrawal and early abstinence are known to cause a hypodopaminergic state and this may have contributed to the acute worsening of psychotic symptoms in this patient when aripiprazole was added.5 The potential of aripiprazole to worsen psychosis needs to be considered when acute deterioration in mental state is noted after its addition.

References

1.
Bandelow M: Aripiprazole, a “Dopamine-serotonin System Stabiliser” in the treatment of psychosis. Ger J Psychiatry 2003; 6:9–16
2.
Ahuja N, Lloyd AJ: Aripiprazole and worsening of psychosis: a case report. J Clin Psychiatry 2007; 68:805–806
3.
Grover S, Sharan P, Gupta N: Aripiprazole worsens psychosis: a case report. Prim Care Companion J Clin Psychiatry 2006; 8:380–381
4.
Selvaraj V, Ramaswamy S, Sharma A, et al.: New-onset psychosis and emergence of suicidal ideation with aripiprazole. Am J Psychiatry 2010; 167:1535–1536
5.
Lingford-Hughes A, Watson B, Kalk N, et al.: Neuropharmacology of addiction and how it informs treatment. Br Med Bull 2010; 96:93–110

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E20
PubMed: 24763776

History

Published online: 1 April 2014
Published in print: Spring 2014

Authors

Affiliations

Jodi Eatt, M.B.B.S.
Dept. of Psychiatry, Rockingham General Hospital, Rockingham, Western Australia, Australia
Sunny Tony Varghese, M.B.B.S., M.D., F.R.A.N.Z.C.P.
Dept. of Psychiatry, Rockingham General Hospital, Rockingham, Western Australia, Australia

Notes

Send correspondence to Dr. Varghese; e-mail: [email protected]

Competing Interests

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share